Business Directory, Press Releases, Jobs, Products, Services, Articles
Businesses Articles Press Releases Follow @PRcom
Press Release Pricing | News by Category | News by Country | News by US Region | Recent News | News on Your Site

Press Releases


Press Release

Receive press releases from ReportsandReports: By Email RSS Feeds:

Dyslipidemia – Pipeline Assessment and Market Forecasts to 2016 Now Available at ReportsandReports

GlobalData, the industry analysis specialist, has released a new report, “Dyslipidemia – Pipeline Assessment and Market Forecasts to 2016.” The report is an essential source of information and analysis on the global dyslipidemia market. The report identifies the key trends shaping and driving the global dyslipidemia market.

Dallas, TX, June 26, 2010 --( ReportsandReports Announce it Will Carry Dyslipidemia – Pipeline Assessment and Market Forecasts to 2016 Market Research Report in its Store.

Browse the complete Report on:

GlobalData, the industry analysis specialist, has released a new report, “Dyslipidemia – Pipeline Assessment and Market Forecasts to 2016.” The report is an essential source of information and analysis on the global dyslipidemia market. The report identifies the key trends shaping and driving the global dyslipidemia market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the existing market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global dyslipidemia sector. GlobalData estimated the global dyslipidemia market to be valued at $34.4 billion in 2009. It is expected to decline at a compound annual growth rate (CAGR) of approximately 3.7% from $34.4 billion in 2009 to $26.3 billion by 2016. Although the cardiovascular market expanded considerably between 2004 and 2008, growth in the seven major markets is expected to slow down from 2012. The decline is sales during this period would be due to the expiry of leading brands’ patents. Pfizer’s Lipitor, which is a major blockbuster in the dyslipidemia market, is set to expire in 2011 along with Trilipix’s. Zetia, Vyotrin, Simcor, Lescol, Livalo and Lovaza are set to expire between 2012 and 2014. Growth in the market is being driven by the expansion of sales in existing classes, the launch of major new products with safety and convenience advantages such as once-daily administration and combinational therapies. Cetriad, belonging to AstraZeneca and Abbott Laboratories, has been filed with the US FDA and is currently the most anticipated drug. GlobalData found that there are over 98 molecules in various stages of the pipeline. Cetriad, Trilipix in combination with atorvastatin, Trilipix in combination with simvastatin, RG1658, MK-0524A, Caduet, GFT-505, AEGR-733, AMR-101 and MK-859 are some of the promising molecules in late stage dyslipidemia pipeline.

These molecules differ in their targets and mechanisms of action from the existing therapies. Most of these molecules are combination products of already marketed drugs. Novelty exists in terms of using two different drugs in combination in order to provide better efficacy. Some of the drugs in the late stage pipeline such as GFT 505 and MK-0524A are completely novel to the dyslipidemia market. Though the dyslipidemia pipeline is strong in terms of first-in-class and me-too products, only a small number of products are expected to enter the market before 2016. Inspite of its strong pipeline, the dyslipidemia market is declining due to the expiries of the patents of its major blockbuster drugs. GlobalData has found that the available treatment options have been moderately successful in meeting the market demand. The current therapeutics compete to provide rapid decreases in LDL-C (low density lipoprotein-cholesterol), TG (tryglycerides), TC (total cholesterol) levels and increases in HDL-C (high density lipoprotein-cholesterol) levels and improve patients’ overall quality of life. The treatments approved for the treatment of dyslipidemia also minimize the risk of cardiovascular disorders.

Overall, there is strong competition among the currently marketed products for symptomatic treatment of the disease. Although the current dyslipidemia treatments are only symptomatic, they treat patients effectively. Hence the market for dyslipidemia is strong. However, safety remains a concern as antidyslipidemic drugs are associated with serious adverse effects such as myopathy or rhabdomylosis, liver disease and increased liver enzymes. There is significant potential for any new entrant that can cater to these unmet needs. A product with disease modifying mechanisms, a better safety profile and good efficacy is sure to achieve blockbuster drug status. Thus, a strong opportunity exists for any drug that offers better efficacy and safety than is provided by the current players.

The scope of the report includes:

Annualized global dyslipidemia market revenues data from 2001 to 2009, forecast forward for 7 years to 2016.
Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends.
Analysis of the current and future market competition in the global dyslipidemia market.
Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for the future market associated with dyslipidemia

Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global dyslipidemia market.
Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global dyslipidemia market in future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
What’s the next big thing in the global dyslipidemia market landscape? – Identify, understand and capitalize.

Contact Information
Akshata Patil

Click here to view the list of recent Press Releases from ReportsandReports
Promote Your Business